| |
Thursday, April 6, 2023 | 11am ET / 8am PT In this webinar, we show how we used Nunchuck to make LNPs in small-volume screening runs and bulk formulations. The complete workflow will be illustrated, from the testing of flow rates in initial formulations to the final assessment of mRNA expression in multiple cell types, showing successful transfection of cells by the LNPs. Register now.
|
|
Today's Big NewsMar 30, 2023 |
|
April 3 - 4, 2023 | San Diego, CA Be a part of a learning experience developed by our esteemed Advisory Board who are leaders in the life science communications space. Time is running out! Register Today
|
|
| By Max Bayer Former Johnson & Johnson R&D chief Mathai Mammen has landed a new role, taking the reins as CEO of FogPharma. The well-financed biotech is aiming to launch its first asset into the clinic by the middle of the year. |
|
|
|
By Nick Paul Taylor EIP Pharma has mapped out a financial freeway to the delivery of phase 2b on an ex-Vertex molecule. By merging with the floundering Diffusion Pharmaceuticals, the biotech is set to secure a Nasdaq listing and enough money to complete a clinical trial in dementia with Lewy bodies. |
By Gabrielle Masson Emerging biopharmas have gradually taken over the R&D pipeline, producing two-thirds of all new drugs in 2022, a finding one financial expert called "stunning." |
By Annalee Armstrong Gene editing has been limited to a few sites in the body because of restrictive delivery mechanisms. Scientists have now discovered a tiny needle that a bacteria uses to kill insect cells that could someday widen the world of gene editing therapeutics. |
By Nick Paul Taylor Confo Therapeutics’ business development team is on a roll. Weeks after licensing its lead candidate to Eli Lilly, the Belgian biotech has landed a 168 million euro deal with Daiichi Sankyo to discover small-molecule agonists of a central nervous system target. |
By Gabrielle Masson While clinical trial activity was strong in 2022 following a pandemic-induced dip, many trends resumed their pre-COVID trajectory—including plummeting diversity in clinical trials. |
By James Waldron Nanoscope has scored a phase 2 win for its gene therapy using light-sensitive molecules to treat retinal disease, keeping alive the hope of a first treatment to improve vision in these patients. |
By Max Bayer BriaCell is forming a new spinout company with the backend of its pipeline. The hope is that the assets can be better developed under a separate balance sheet. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Conor Hale ICU Medical has placed itself in the running to serve as the new corporate home of Medtronic’s patient monitoring and hospital ventilator businesses, according to a report from Reuters. |
By Joseph Keenan Inato, a clinical trial company based in France, has hauled in $22 million in series A2 funding, which will be used for international growth, product innovation and to attract employees. |
By Kevin Dunleavy Based on 2021 spending data from the U.S. Centers for Medicare & Medicaid Services, Moody’s has identified drugs that appear destined to be subject to price negotiations in 2026. Bristol Myers Squibb and Pfizer’s Eliquis leads the pack, with drugs from AbbVie, Johnson & Johnson and Novo Nordisk also making appearances. |
By Robert King A new bipartisan Senate bill aims to crack down on Medicare Advantage up-coding that can drive up plan payments, hoping to settle a feud between CMS and health insurers. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ Connect with senior executives in Medical Affairs, MSL and IIT to share best practices. Register Today & save $200 from now until April 7th!
|
|
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperThis paper describes the key elements of good US/EU corporate governance for US-based biopharma companies in operating Europe. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
